174 related articles for article (PubMed ID: 12520624)
1. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.
Thomsen MS; Chassard D; Evène E; Nielsen KK; Jørgensen M
J Clin Pharmacol; 2003 Jan; 43(1):23-8. PubMed ID: 12520624
[TBL] [Abstract][Full Text] [Related]
2. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
Hatorp V; Huang WC; Strange P
J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide pharmacokinetics in healthy young adult and elderly subjects.
Hatorp V; Huang WC; Strange P
Clin Ther; 1999 Apr; 21(4):702-10. PubMed ID: 10363735
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
Hatorp V; Oliver S; Su CA
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
8. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.
Zhu J; Song M; Tan HY; Huang LH; Huang ZJ; Liu C; Fu ZM; Huang YY; Tan ZR; Chen XP; Yuan H; Yang GP
Pak J Pharm Sci; 2013 May; 26(3):577-84. PubMed ID: 23625433
[TBL] [Abstract][Full Text] [Related]
9. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
10. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects.
Hoelscher D; Chu PL; Lyness W
Clin Drug Investig; 2008; 28(9):573-82. PubMed ID: 18666804
[TBL] [Abstract][Full Text] [Related]
13. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
16. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Pei Q; Liu JY; Yin JY; Yang GP; Liu SK; Zheng Y; Xie P; Guo CX; Luo M; Zhou HH; Li X; Liu ZQ
Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
[TBL] [Abstract][Full Text] [Related]
18. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
